183557-77-9

Basic information

• Product Name: (4-morpholin-4-yl-phenyl)-amide
• Synonyms: (4-morpholin-4-yl-phenyl)-amide
• CAS NO: 183557-77-9
• Molecular Weight: 206.244
• Mol File: 183557-77-9.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (4-morpholin-4-yl-phenyl)-amide(CAS DataBase Reference)
• NIST Chemistry Reference: (4-morpholin-4-yl-phenyl)-amide(183557-77-9)
• EPA Substance Registry System: (4-morpholin-4-yl-phenyl)-amide(183557-77-9)

Safety Data

• Hazardous Substances Data: 183557-77-9(Hazardous Substances Data)

Usage

Description

(4-morpholin-4-yl-phenyl)-amide is a chemical compound that features a morpholine ring and a phenyl group connected to an amide functional group. This structure endows the molecule with distinctive characteristics, such as the capacity to engage in hydrogen bonding and a relatively low reactivity. It serves as a valuable building block in the synthesis of a variety of organic compounds and holds promise for applications in different industries.

Uses

Used in Pharmaceutical Industry:
(4-morpholin-4-yl-phenyl)-amide is utilized as a starting material for the development of drug candidates due to its unique structural properties and potential for hydrogen bonding, which can be beneficial in the design of new medications.
Used in Specialty Chemicals and Materials Production:
(4-morpholin-4-yl-phenyl)-amide is also employed in the creation of specialty chemicals and materials, where its specific bonding capabilities and reactivity profile can contribute to the development of novel products with tailored properties for various applications.
As research and development in chemical synthesis and material science continue to advance, it is likely that additional uses for (4-morpholin-4-yl-phenyl)-amide will be discovered, expanding its relevance and application across multiple fields.

Upstream product

• 110-91-8 morpholine 
• 698-67-9 p-bromobenzamide 
• 824-75-9 p-fluorobenzamide 
• 10282-31-2 4-morpholinobenzonitrile 
• 2835-68-9 4-aminobenzamide 
• 111-44-4 3-oxa-1,5-dichloropentane 
• 7470-38-4 4-morpholin-4-yl-benzoic acid 
• 19614-15-4 4-(morpholin-4-yl)benzoic acid ethyl ester 
• 451-46-7 4-fluorobenzoic acid ethyl ester 
• 23676-05-3 4-morpholin-4-yl-benzoic acid methyl ester 

Downstream Products

• 214759-74-7 1-(4-morpholin-4-ylphenyl)methanamine 
• 1542257-72-6 3-(2-(4-(morpholinyl)phenyl)thiazol-5-yl)-2,6-dimethylpyrimidine-4(3H)-one 
• 519056-60-1 4-(morpholino)thiobenzamide 
• 1542258-99-0 4-(4-(5-nitrothiazol-2-yl)phenyl)morpholine 
• 1542258-98-9 4-(4-(thiazol-2-yl) phenyl) morpholine 
• 1542259-00-6 2-(4-morpholinophenyl) thiazol-5-amine 

Relevant articles and documents

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors

Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50 values less than 5.0 nM. Significant antiproliferative effects on both FGFR1/2 and VEGFR2 aberrant cancer cells were observed. In the SNU-16 xenograft model, compound 25a showed tumor growth inhibition rates of 25.0% and 81.0% at doses of 10 mg/kg and 50 mg/kg, respectively, with 5% and 10%body weight loss. In view of the synergistic potential of FGFs and VEGFs in tumor angiogenesis observed in preclinical studies, the FGFR/VEGFR2 dual inhibitor 25a may achieve better clinical benefits.

A Method for Identifying and Developing Functional Group Tolerant Catalytic Reactions: Application to the Buchwald-Hartwig Amination

Transition-metal catalysis has revolutionized organic synthesis, but difficulties can often be encountered when applied to highly functionalized molecules, such as pharmaceuticals and their precursors. This results in discovery collections that are enrich

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.